By Molika Ashford
The company plans two new versions of its MyPRS test later this year, including a pharmacogenomic enhancement called MyPRS RX and a version called MyPRS Plus that will perform myeloma subgroup analysis.
Startup Signal Genetics has decided to partner with specialty labs that have existing relationships with its target market instead of creating its own sales organization.
Caris Target Now for Ovarian Cancer
Sheila Walcoff, Amy Jensen Cunniffe, Gary Palmer
Amy Jensen Cunniffe, Leonhard Pollack, Mark Pittman
Caris will exclusively offer Signal's Myeloma Prognostic Risk Signature, or MyPRS, test to community-based hematologists and medical oncologists across the US.
Bernd Brust, Nicolas Barthelemy, Andy Tasinato, Elodie Ristorcelli, Gherici Hassaine, Dan Holterman, Wang-Juh Chen, Jorge Schettini, Tassilo Hornung
23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.
China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.
In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.
NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.